Evaluation of new drugs in daily clinical practice: anti-TNF alpha in rheumatoid arthritis patients.

Doctoral thesis OPEN
Kievit, W.;
(2008)
  • Publisher: [S.l. : s.n.]

The objective of this thesis was to explore the value and the validity of data collected in daily clinical practice for drug evaluation and cost-effectiveness studies, using data collected on TNFa blocking agents in rheumatoid arthritis. First, the need for and value of... View more
  • References (21)
    21 references, page 1 of 3

    Kwoh CK, Anderson LG, Greene JM, Johnson DA, O'Dell R, Robbins ML, Roberts WN, Simms RW, Yood RA. Guidelines for the management of rheumatoid arthritis - 2002 update. Arthritis and Rheumatism 2002; 46:328-346.

    Gremillion RB, van Vollenhoven RF. Rheumatoid arthritis. Designing and implementing a treatment plan. Postgrad Med 1998; 103:103-108.

    Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005; 52:2616-2624.

    Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328-346.

    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:353- 363.

    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259.

    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-1939.

    TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007; Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005; 64 Suppl 4:iv2-14.

    Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44:157-163.

    Modified Disease-Activity Scores That Include 28-Joint Counts - Development and Validation in A Prospective Longitudinal-Study of Patients with Rheumatoid-Arthritis. Arthritis and Rheumatism 1995; 38:44-48.

  • Metrics
Share - Bookmark

  • Download from
    Radboud Repository via NARCIS (Doctoral thesis, 2008)
  • Cite this publication